BCAL DIAGNOSTICS LIMITED - Announcements

Market Cap $27.75M Add to my watchlist

Healthcare Biotechnology

BCAL Diagnostics Limited is an Australia-based biotechnology company, which is focused on... BCAL Diagnostics Limited is an Australia-based biotechnology company, which is focused on improving health outcomes for women. The Company’s principal activities include the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer, including preparation for clinical trials. It developed a blood screening test to be used alongside breast cancer screening methods. The technology initially complements imaging technologies, such as the mammogram, while it further progresses the development of a monitoring and screening test suitable for women of all ages and backgrounds in any location. Its BCAL test is a lipid biomarker blood (Breast Cancer Associated Lipids test) test with the potential to be used for breast cancer prevention, screening, and monitoring. The Company has partnered with Precion Inc. to optimize protocols and procedures for the clinical studies required for regulatory approvals across several jurisdictions.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

BDX	Appendix 4C Revised		04/02/22	92.74KB	Share
BDX	Becoming a substantial holder		31/01/22	202.08KB	Share
BDX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/01/22	113.43KB	Share
BDX	Dr John Hurrell Appointed Chief Executive Officer	PRICE SENSITIVE	11/01/22	50.17KB	Share
BDX	Application for quotation of securities - BDX		29/12/21	25.29KB	Share
BDX	Change In Directors Interest Notice - Correction		13/12/21	78.7KB	Share
BDX	Directors Change of Interest Notice X 2		13/12/21	73.41KB	Share
BDX	Results of Meeting		23/11/21	106.33KB	Share
BDX	Results of Meeting		22/11/21	104.99KB	Share
BDX	AGM Presentation		22/11/21	4.1MB	Share
BDX	Addendum to Appendix 4C		08/11/21	132.61KB	Share
BDX	Strong Cohort 4 Testing Data Demonstrates Value of BCAL Test	PRICE SENSITIVE	03/11/21	185.43KB	Share
BDX	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/10/21	233.3KB	Share
BDX	Ceasing to be a substantial holder		26/10/21	81.62KB	Share
BDX	letter to Shareholders AGM Notice		21/10/21	183.36KB	Share
BDX	Notice of Annual General Meeting/Proxy Form		21/10/21	534.61KB	Share
BDX	AGM Date and Closing Date for Director Nominations		04/10/21	144.85KB	Share
BDX	Appendix 4G and Corporate Governance Statement		28/09/21	578.08KB	Share
BDX	Annual Report to shareholders		28/09/21	1.93MB	Share
BDX	Change of Director's Interest Notice		13/09/21	213.42KB	Share
BDX	Change of Director's Interest Notice		07/09/21	213.13KB	Share
BDX	Australian Clinical Studies Launched	PRICE SENSITIVE	03/09/21	137.38KB	Share
BDX	Preliminary Final Report	PRICE SENSITIVE	31/08/21	463.84KB	Share
BDX	Market Update	PRICE SENSITIVE	17/08/21	167.62KB	Share
BDX	Becoming a substantial holder		22/07/21	85.02KB	Share
BDX	BCAL Diagnostics to List on ASX After Raising $10m in IPO		21/07/21	164.1KB	Share
BDX	BCAL Diagnostics Investor Presentation		21/07/21	2.01MB	Share
BDX	Initial Directors Interest Notice X 5		21/07/21	509.71KB	Share
BDX	Initial Substantial Shareholder Notice X 4		21/07/21	1.21MB	Share
BDX	Pre-Quotation Disclosure		19/07/21	113.9KB	Share
BDX	Top 20 Holders		19/07/21	74.31KB	Share
BDX	Distribution Schedule		19/07/21	63.35KB	Share
BDX	Securities Trading Policy		19/07/21	100.65KB	Share
BDX	Equity Incentive Plan Rules		19/07/21	289.31KB	Share
BDX	Terms & Conditions of Options		19/07/21	157.25KB	Share
BDX	Interim Report 31 December 2020		19/07/21	750.62KB	Share
BDX	Annual Report 30 June 2020		19/07/21	856.05KB	Share
BDX	Annual Report 30 June 2019		19/07/21	786.41KB	Share
BDX	Constitution		19/07/21	709.71KB	Share
BDX	Prospectus		19/07/21	5.2MB	Share
BDX	Appendix 1A and Information Form and Checklist		19/07/21	447.19KB	Share
BDX	ASX Market Release - Admission and Quotation		19/07/21	451.2KB	Share

BDX Appendix 4C Revised
04/02/22		92.74KB	Share
BDX Becoming a substantial holder
31/01/22		202.08KB	Share
BDX Quarterly Activities/Appendix 4C Cash Flow Report
27/01/22	PRICE SENSITIVE	113.43KB	Share
BDX Dr John Hurrell Appointed Chief Executive Officer
11/01/22	PRICE SENSITIVE	50.17KB	Share
BDX Application for quotation of securities - BDX
29/12/21		25.29KB	Share
BDX Change In Directors Interest Notice - Correction
13/12/21		78.7KB	Share
BDX Directors Change of Interest Notice X 2
13/12/21		73.41KB	Share
BDX Results of Meeting
23/11/21		106.33KB	Share
BDX Results of Meeting
22/11/21		104.99KB	Share
BDX AGM Presentation
22/11/21		4.1MB	Share
BDX Addendum to Appendix 4C
08/11/21		132.61KB	Share
BDX Strong Cohort 4 Testing Data Demonstrates Value of BCAL Test
03/11/21	PRICE SENSITIVE	185.43KB	Share
BDX Quarterly Activities/Appendix 4C Cash Flow Report
28/10/21	PRICE SENSITIVE	233.3KB	Share
BDX Ceasing to be a substantial holder
26/10/21		81.62KB	Share
BDX letter to Shareholders AGM Notice
21/10/21		183.36KB	Share
BDX Notice of Annual General Meeting/Proxy Form
21/10/21		534.61KB	Share
BDX AGM Date and Closing Date for Director Nominations
04/10/21		144.85KB	Share
BDX Appendix 4G and Corporate Governance Statement
28/09/21		578.08KB	Share
BDX Annual Report to shareholders
28/09/21		1.93MB	Share
BDX Change of Director's Interest Notice
13/09/21		213.42KB	Share
BDX Change of Director's Interest Notice
07/09/21		213.13KB	Share
BDX Australian Clinical Studies Launched
03/09/21	PRICE SENSITIVE	137.38KB	Share
BDX Preliminary Final Report
31/08/21	PRICE SENSITIVE	463.84KB	Share
BDX Market Update
17/08/21	PRICE SENSITIVE	167.62KB	Share
BDX Becoming a substantial holder
22/07/21		85.02KB	Share
BDX BCAL Diagnostics to List on ASX After Raising $10m in IPO
21/07/21		164.1KB	Share
BDX BCAL Diagnostics Investor Presentation
21/07/21		2.01MB	Share
BDX Initial Directors Interest Notice X 5
21/07/21		509.71KB	Share
BDX Initial Substantial Shareholder Notice X 4
21/07/21		1.21MB	Share
BDX Pre-Quotation Disclosure
19/07/21		113.9KB	Share
BDX Top 20 Holders
19/07/21		74.31KB	Share
BDX Distribution Schedule
19/07/21		63.35KB	Share
BDX Securities Trading Policy
19/07/21		100.65KB	Share
BDX Equity Incentive Plan Rules
19/07/21		289.31KB	Share
BDX Terms & Conditions of Options
19/07/21		157.25KB	Share
BDX Interim Report 31 December 2020
19/07/21		750.62KB	Share
BDX Annual Report 30 June 2020
19/07/21		856.05KB	Share
BDX Annual Report 30 June 2019
19/07/21		786.41KB	Share
BDX Constitution
19/07/21		709.71KB	Share
BDX Prospectus
19/07/21		5.2MB	Share
BDX Appendix 1A and Information Form and Checklist
19/07/21		447.19KB	Share
BDX ASX Market Release - Admission and Quotation
19/07/21		451.2KB	Share

REFRESH

First

(20min delay)
Last 11.0¢		Change -0.005(4.35%)		Mkt cap ! $27.75M

Open	High	Low	Value	Volume
11.0¢	11.0¢	11.0¢	$7.843K	71.29K

Buyers (Bids)

No.	Vol.	Price($)
3	36514	10.5¢

Sellers (Offers)

Price($)	Vol.	No.
11.0¢	20000	1

View Market Depth

No.	Vol.	Price($)
3	36514	0.105
3	106000	0.100
1	100000	0.098
1	100000	0.092
2	566693	0.091

Price($)	Vol.	No.
0.115	104770	1
0.120	63332	1
0.125	100000	1
0.130	136123	2
0.140	40076	1

Last trade - 11.00am 24/05/2024 (20 minute delay)


Last 11.5¢		Change -0.005 ( 4.55 %)
Open	High	Low	Volume
10.5¢	11.5¢	10.5¢	17649
Last updated 11.27am 24/05/2024 ?

BDX (ASX) Chart

BCAL DIAGNOSTICS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available